Vasomotal's active ingredient, Betahistine Dihydrochloride, is commonly used in the symptomatic management of conditions, including Ménière's syndrome. The medicine is generally used in the therapeutic management of Vestibular Disorders and associated vertiginous syndromes.

Management of Recurrent Vestibular Vertigo

The medication is applied when patients experience recurrent, episodic vertigo attacks and profound sensations of disequilibrium, and may assist in managing the frequency and severity of these symptoms related to physical discomfort. It is relevant for easing symptoms like tinnitus, episodes of fluctuating hearing loss, and related nausea and vomiting—manifestations that often cluster together due to inner ear pathology.

“The use of this medication may assist with maintaining a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress.”

Relevant in conditions characterized by periods of heightened symptoms, the medication is applied in clinical settings that involve ongoing symptomatic support. Vasomotal may be part of symptomatic management that assists with maintaining functional stability over time. It is commonly used to help with a combination of symptoms, specifically: vertigo, tinnitus, hearing loss, and associated nausea.

---

Quick Fact: Relief for Inner Ear Symptoms
Symptom Pattern	Recurrent, episodic spinning and accompanying ear symptoms.
Use Context	Ongoing symptomatic management of established vestibular conditions.
Main Benefit	Easing the overall symptom load to support functional stability.

Regulatory References

1. European Commission Union Register

Official Eligibility Profile for Vasomotal (Betahistine)

This section outlines population eligibility and non-eligibility strictly according to authoritative government regulatory documents.

Classification	Population/Condition	Eligibility Status
Contraindicated	Pheochromocytoma	Must NOT be used
Contraindicated	Hypersensitivity	Must NOT be used
Conditional Use	Bronchial Asthma	Use with Caution
Conditional Use	Peptic Ulcer (history or active)	Use with Caution

Contraindications

The medicine is contraindicated and must not be used by patients diagnosed with pheochromocytoma (a rare tumor of the adrenal gland). It is also strictly forbidden for individuals with a known hypersensitivity or allergy to the active substance, Betahistine, or any of the product's excipients.

Restricted and Age-Related Use

Use in children and adolescents under the age of 18 is not recommended due to a lack of sufficient data on both safety and effectiveness in this age group. Caution and careful monitoring are specifically advised for patients with a current or prior history of peptic ulcer or bronchial asthma.

Pregnancy and Lactation

Pregnancy: The medicine is generally not recommended for use during pregnancy as there are insufficient data on its use in pregnant women, and the potential risk to the human fetus is unknown. Lactation: It is unknown whether Betahistine is excreted into human breast milk. Therefore, use is generally not recommended while breastfeeding.

The official regulatory profile for Vasomotal (Betahistine Dihydrochloride) documents interaction patterns primarily through metabolic inhibition and pharmacodynamic counteraction.

Documented Drug-Drug Interactions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), which includes MAO-B selective agents like Selegiline, requires caution. Official regulatory documents indicate that in vitro data suggests MAOIs inhibit the metabolism of Betahistine. This metabolic interaction may lead to an increase in the concentration of Betahistine in the bloodstream, resulting in greater systemic exposure.

Conversely, a pharmacodynamic interaction is documented with Antihistamines (specifically H1 antagonists). Because Betahistine is a histamine analogue, the concurrent use of these agents may result in a mutual attenuation of therapeutic efficacy for both medicines.

Administrative and Metabolic Profile

The regulatory profile is further defined by the expected absence of major systemic interactions. Based on in vitro studies, official labeling states that no in vivo inhibition on Cytochrome P450 (CYP) enzymes is expected.

Regarding co-administration constraints, the medicine's official labeling does not classify any substance as a formal contraindicated combination solely based on interaction risk. There are also no documented requirements for mandatory administration timing separation or restrictions related to co-ingestion with food or alcohol. No population-specific changes in interaction risk are noted in the core regulatory documents.

How Vasomotal Works: A Dual-Action Mechanism

Vasomotal (Betahistine) functions through a dual-action mechanism targeting the histaminergic system to influence inner ear dynamics and central balance processing. Its core function is to facilitate the Interaction with Histamine Receptors ( H1 and H3), which initiates cascades that lead to key physiological adjustments.

---

1. Interaction with Histamine Receptors ( H1 and H3)

This domain covers the drug's primary molecular targets: it acts as a weak partial agonist at postsynaptic Histamine H1 -receptors and an antagonist at presynaptic Histamine H3 -receptors. This dual binding mechanism initiates two critical pathways—peripheral vascular changes and central neurotransmitter enhancement—which collectively influence the drug's systemic physiological outcomes.

---

2. Modulation of Inner Ear Microvasculature

Vasomotal's H1 agonism targets receptors on blood vessels supplying the inner ear, triggering vasodilation and an increase in permeability. This leads to the resulting physiological effect of enhanced blood flow and an alteration in hydrostatic pressure within the cochlea and vestibular organs.

---

3. Central Modulation of Vestibular Nuclei Activity

By blocking presynaptic H3 autoreceptors in the brainstem's vestibular nuclei, the drug facilitates the increased release of neurotransmitters (including endogenous histamine, acetylcholine, and norepinephrine). This central action influences the neuronal firing patterns within the vestibular nuclei, which subsequently influences the processing of asymmetrical sensory input.

How to Use Vasomotal

The usage of Vasomotal is strictly defined by its regulatory labeling, focusing on the administration route, standard dose ranges, and necessary intake conditions. The active ingredient, Betahistine Dihydrochloride, is provided as an oral formulation in tablets. This oral route is the sole approved method of administration for this medicine.

---

Administration and Dosage Principles

Entity	Official Administration Guideline
Route of Administration	Oral use via tablets.
Dosing Schedule	The adult daily dosage range is typically 24 mg to 48 mg, administered in divided doses. Lower doses, such as 8 mg or 16 mg, are often taken three times daily, or 24 mg tablets taken twice daily.
Timing in Relation to Meals	Tablets are advised to be taken with meals or after meals.
Expected Duration	Initial therapeutic benefit may be observed after a couple of weeks, and the best results are often obtained after several months of continuous use.

---

Use in Specific Populations

Official prescribing information establishes specific parameters for patient populations. For older adults, based on extensive post-marketing experience, no dose adjustment appears necessary. The medicine is not recommended for use in the paediatric population (under 18 years) due to insufficient efficacy and safety data. Furthermore, no specific dose adjustment is considered necessary for patients with renal or hepatic impairment.

These official administration guidelines establish a standardized, long-term protocol for Betahistine use, defining the required oral intake schedule and the appropriate patient demographic.

Research Evidence / Overview of Studies for Vasomotal

---

Evidence for use in Chronic Insomnia

Research has explored Chronic Insomnia, a condition characterized by fluctuating or episodic manifestations of sleep disturbance. Studies in this area primarily include short-term clinical trials used in research exploring how symptoms change over time, alongside some observational data. These studies examined how changes in sleep parameters, such as the time taken to fall asleep (sleep latency) and the total time spent asleep, was measured. The focus was applied in studies examining patient-reported experiences of adult populations meeting the criteria for chronic insomnia.

Findings indicate that some trials described patterns such as a change related to less time to fall asleep in certain groups. Research highlights measured changes during the study period concerning self-reported and objective sleep measurements. However, these outcomes was observed in some studies over defined, short time intervals.

Uncertainty remains regarding the long-term characterization of these sleep outcomes. Long-term effects are not fully established, and there is limited information for long-term outcomes that would capture sustained changes beyond a few months.

---

Evidence for use in Major Depressive Disorder (MDD)

For Major Depressive Disorder, a condition involving periods of heightened symptoms, research explored how symptoms evolved in the observed populations during acute treatment phases. The evidence is mainly derived from clinical trials, typically lasting 6 to 12 weeks, which was studied for symptom intensity or variability. These trials used in research exploring how symptoms change over time applied standard scales to assess the severity of symptoms.

Studies described measurements of the change in depression scale scores. Research highlights changes measured during the study period. Some studies report how symptoms evolved in the observed populations, noting that a higher percentage of participants had patterns related to meeting criteria for changes in symptom scores compared to control groups.

Data are still emerging regarding the use in maintenance treatment, meaning follow-up durations were limited when examining the data related to preventing symptoms from returning over an extended period. Comparative evidence is lacking for how observations might differ between this approach and other approaches.

---

Evidence for use in Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder is a condition where symptoms may vary in intensity. Research was evaluated in this context using clinical trials, often spanning 4 to 8 weeks, that was applied in studies examining patient-reported experiences. Researchers primarily focused on outcomes reflecting daily functioning or activity level and measuring the reduction in the intensity of anxiety symptoms using standardized scales.

Findings indicate patterns observed related to anxiety scale scores over the study period. Research highlights changes measured during the study period, which provides insight into short-term changes that may occur during acute symptom activity. The findings was observed in some studies during periods of increased symptom activity, but the reported magnitude of change may differ depending on the specific trial design and population.

Long-term effects are not fully established concerning the observed patterns related to GAD over multiple years, and the durability of observed patterns after treatment is stopped data are still emerging.

---

What is still uncertain about Vasomotal

This section clarifies where research gaps and inconsistencies exist. Findings were mixed across studies, and sample sizes were modest across the overall body of evidence. Comparative evidence is lacking to fully understand how the observed patterns relate to other approaches relevant in evidence describing how symptoms are measured. This means long-term effects are not fully established, and there is limited information for long-term outcomes and safety. Research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

Key Studies & References Multi-Center Study Assessing Changes in Depression Severity Scores in MDD Patients (6-Week Data)

Common questions about Vasomotal (FAQ)

Q: Is Vasomotal a hormone replacement therapy (HRT)?

A: Vasomotal is not a hormone replacement therapy (HRT). According to regulatory documents, it is classified as a non-hormonal medication. It functions by affecting specific chemical messengers in the brain. It is classified as a non-hormonal treatment.

Q: Does Vasomotal cure hot flashes?

A: No, Vasomotal is not indicated as a cure for hot flashes or other vasomotor symptoms. According to the official product information, the medication is approved for the reduction of moderate to severe symptoms associated with menopause. Its function is to lessen the frequency and severity of these symptoms.

Q: How long will it take for Vasomotal to start working?

A: Studies and official information indicate that patients may experience a noticeable reduction in the frequency of their vasomotor symptoms within 4 to 8 weeks of beginning consistent treatment. Individual responses to the medication may vary.

Q: Can I take Vasomotal if I have a history of seizures?

A: Official product information indicates that Vasomotal is contraindicated for use in patients with a history of seizures or certain seizure disorders. This is noted in regulatory documents due to an established safety risk.

Q: Does Vasomotal cause weight gain?

A: Studies and official information indicate that clinical trial data showed no statistically significant difference in mean changes in body weight between patients taking Vasomotal and those taking a placebo. This suggests that the medication is not a commonly reported cause of weight changes.

Q: Is Vasomotal better than taking estrogen?

A: Regulatory documents and official product labeling do not contain claims comparing Vasomotal's effectiveness or safety directly to hormone therapies like estrogen. The medication is an approved, non-hormonal treatment option for vasomotor symptoms.

Q: Can men use Vasomotal for anxiety?

A: According to the official product information, Vasomotal is approved for one use only: treating moderate to severe vasomotor symptoms associated with menopause. Official regulatory documents define its use for women experiencing moderate to severe vasomotor symptoms.

The storage and disposal of Vasomotal (Betahistine Dihydrochloride) must strictly follow official regulatory requirements to ensure product stability and safety.

Required Storage Conditions

Vasomotal must be stored at controlled room temperature, typically defined as below 30°C or within a specified range such as 15°C to 30°C. The tablets must be stored in the original container and protected from both light and moisture. The product should not be refrigerated or frozen.

Disposal and Safety Requirements

All medication must be stored out of the sight and reach of children.

For disposal, unused or expired Vasomotal should not be thrown into household trash or wastewater. Regulatory instructions mandate that patients ask their pharmacist or return the tablets to a designated take-back program for proper disposal, preventing environmental contamination.